HSBC Small Cap Fund
The Scheme will primarily be a diversified equity fund which will invest predominantly in small cap stocks to generate long term capital appreciation.
Growthvine rating: 3/5 — ranked #16 of 37 in category.
Fund basics
| Category | Equity: Small Cap |
|---|
| NAV | ₹90.99 (as of 2026-08-21) |
|---|
| AUM | ₹17,830 Cr |
|---|
| Expense ratio | 1.43% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Venugopal Manghat |
|---|
| Exit load | For units in excess of 10% of the investment, 1% will be charged for redemption within 365 days |
|---|
Performance & risk
| Sharpe ratio | 0.45 |
|---|
| Standard deviation | 21.73% |
|---|
| Max drawdown | -27.33% |
|---|
| Alpha | -0.6 |
|---|
| Beta | 0.98 |
|---|
Over 5 years, captured 88.1% of NIFTY Smallcap 250's upside and 84.3% of its downside.
Market cap allocation
| Large cap | 2.8% |
|---|
| Mid cap | 22.7% |
|---|
| Small cap | 74.5% |
|---|
Concentration
| Top 5 holdings | 10.4% |
|---|
| Top 10 holdings | 19.0% |
|---|
| Total holdings | 108 |
|---|
| Index overlap | 28.6% |
|---|
| Active share | 71.4% |
|---|
Top holdings
- Federal Bank Ltd. — 2.3%
- Karur Vysya Bank Ltd. — 2.2%
- Apar Industries Ltd — 2.0%
- Sai Life Sciences Limited — 2.0%
- Radico Khaitan Ltd. — 1.9%
- PNB Housing Finance Limited — 1.8%
- Aster DM Healthcare Limited — 1.8%
- Neuland Laboratories Limited. — 1.7%
- Ather Energy Limited — 1.7%
- Vijaya Diagnostic Centre Limited — 1.7%
Top sectors
- Banking & Financial — 16.1%
- Industrial Products — 14.6%
- Pharma & Biotech — 9.2%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 16.1% | Q2 | #14 of 34 |
| 2025 | -11.5% | Q4 (Bottom) | #28 of 30 |
| 2024 | 28.5% | Q2 | #8 of 28 |
| 2023 | 46.1% | Q2 | #8 of 24 |